Bondarenko, I., Gladkov, O. A., Elsaesser, R., Buchner, A., & Bias, P. (2013). Efficacy and safety of lipegfilgrastim versus pegfilgrastim: A randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BioMed Central.
Style de citation ChicagoBondarenko, Igor, Oleg A. Gladkov, Reiner Elsaesser, Anton Buchner, et Peter Bias. Efficacy and Safety of Lipegfilgrastim Versus Pegfilgrastim: A Randomized, Multicenter, Active-control Phase 3 Trial in Patients With Breast Cancer Receiving Doxorubicin/docetaxel Chemotherapy. BioMed Central, 2013.
Style de citation MLABondarenko, Igor, et al. Efficacy and Safety of Lipegfilgrastim Versus Pegfilgrastim: A Randomized, Multicenter, Active-control Phase 3 Trial in Patients With Breast Cancer Receiving Doxorubicin/docetaxel Chemotherapy. BioMed Central, 2013.